Natixis Iovance Biotherapeutics, Inc. Transaction History

Natixis

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$5.36 - $9.06 $80,126 - $135,437	14,949 Added 1437.4%	15,989 $112,000
Q4 2022 Feb 24, 2023	BUY	$5.62 - $10.0 $5,844 - $10,400	1,040 New	1,040 $6,000
Q2 2022 Aug 12, 2022	SELL	$6.38 - $18.33 $912,595 - $2.62 Million	-143,040 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$12.38 - $19.1 $1.77 Million - $2.73 Million	143,040 New	143,040 $2.38 Million
Q3 2021 Nov 12, 2021	SELL	$20.35 - $26.63 $226,515 - $296,418	-11,131 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$16.33 - $33.07 $181,769 - $368,102	11,131 New	11,131 $290,000

314

241M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.24B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.